Regardless of the sequential decrease in Current Liabilities, during the second quarter 2026, Quick Ratio deteriorated to 0.01 below Northwest Biotherapeutics Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Northwest Biotherapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 3821 to 4322.

Explain Quick Ratio?
How much Cash & cash equivalents NWBO�s has?
What are NWBO�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NWBO/financial-strength

https://api.csimarket.com/api/v1/companies/NWBO/fundamentals

https://api.csimarket.com/api/v1/companies/NWBO/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NWBO Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-48.78 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	-86.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.01	Subscribe	Subscribe	Subscribe	Subscribe
NWBO's Total Ranking	# 4322	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-48.2 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-66.69 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 903
Overall Market	# 4322

Quick Ratio Statistics
High	Average	Low
0.94	0.1	0
(Dec 31 2013)		(Jun 30 2017)

Financial Statements
Northwest Biotherapeutics Inc's Current Liabilities	$ 43 Millions	Visit NWBO's Balance sheet
Northwest Biotherapeutics Inc's Cash & cash equivalent	$ 1 Millions	Visit NWBO's Balance sheet
Source of NWBO's Sales		Visit NWBO's Sales by Geography

Cumulative Northwest Biotherapeutics Inc's Quick Ratio

NWBO's Quick Ratio for the trailling 12 Months

NWBO Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	3.64 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	-18.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.03	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4125	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-11.82 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	-27.16 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NWBO Financial Strength Comparisons >> Go to Compare NWBO Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in NWBO's Current Liabilities to $42.98 millions, cumulative Quick Ratio to 0.03 below the NWBO average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Northwest Biotherapeutics Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3207 to 4125.

Explain Quick Ratio?
How much Cash & cash equivalents NWBO�s has?
What are NWBO�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 445
Healthcare Sector	# 913
Within the Market	# 4125

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.36	0.09	0
(Mar 31 2014)		(Mar 31 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Bioxytran Inc	0.03	$ 0.177 Millions	$ 5.275 Millions
Cdt Equity Inc	0.03	$ 0.700 Millions	$ 23.351 Millions
Shuttle Pharmaceuticals Holdings Inc	0.03	$ 0.102 Millions	$ 3.481 Millions
Northwest Biotherapeutics Inc	0.01	$ 0.595 Millions	$ 42.982 Millions
Oncotelic Therapeutics Inc	0.01	$ 0.186 Millions	$ 17.907 Millions
Os Therapies Incorporated	0.01	$ 0.205 Millions	$ 20.653 Millions
Celularity Inc	0.01	$ 0.586 Millions	$ 59.738 Millions
The Greater Cannabis Company Inc	0.01	$ 0.000 Millions	$ 0.012 Millions
Chemocentryx Inc.	0.01	$ 1.253 Millions	$ 139.868 Millions
NIKA PHARMACEUTICALS, INC	0.01	$ 0.003 Millions	$ 0.341 Millions
Evofem Biosciences Inc	0.01	$ 0.714 Millions	$ 88.615 Millions
Rain Enhancement Technologies Holdco Inc	0.01	$ 0.071 Millions	$ 13.574 Millions
IMPACT BIOMEDICAL INC.	0.00	$ 0.010 Millions	$ 2.045 Millions
Semnur Pharmaceuticals Inc	0.00	$ 0.039 Millions	$ 10.672 Millions
Cnbx Pharmaceuticals Inc	0.00	$ 0.010 Millions	$ 2.673 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.